From Rural Advocate to National Change-Maker: Sally Turner Steps Up for Eating Disorder Awareness After Persuasive Presentation Training

From Rural Advocate to National Change-Maker: Sally Turner Steps Up for Eating Disorder Awareness After Persuasive Presentation Training
“The masterclass gave me the confidence to share my story and approach sponsors, funders, and decision-makers with clarity and impact,” said Sally.

North Sydney, NSW – June 17, 2025 – In honour of World Eating Disorders Action Day (June 15), rural change-maker Sally Turner is making bold moves to tackle one of the most misunderstood mental health challenges affecting regional Australians.

After participating in Michelle Bowden’s Persuasive Presentation Skills Masterclass (a transformative initiative funded by AgriFutures Australia) Sally has skyrocketed her advocacy efforts and grown The Wattle Project, her grassroots organisation dedicated to improving awareness, education, and access to support for people living with eating disorders in rural and regional communities.

“The masterclass gave me the confidence to share my story and approach sponsors, funders, and decision-makers with clarity and impact,” said Sally. “I left knowing how to tailor my message to inspire action—and it’s working.”

Since completing the course, Sally has:

  • Formed a board and is now applying for Not-for-Profit status
  • Created educational workshops for high school students, parents, and carers
  • Developed a community workshop model now in pilot across regional centres
  • Planned a national sponsorship campaign to fund resource development and workshop delivery
  • Launched the foundations of a Rural Ambassador Network—local voices championing The Wattle Project’s message across the country


These achievements come at a critical time:

  • Over 1.1 million Australians live with an eating disorder
  • Rural sufferers face disproportionate barriers, with treatment often costing $975 per person in travel
  • Stigma, service scarcity, and a lack of trained professionals continue to block support for regional families

Sally’s goal? To see every GP and nurse in rural Australia trained in eating disorder awareness, and every young person in the country’s heartland given the tools to seek help early.

Her persuasive skills are already opening global doors. Sally has just been announced as an Australian delegate to the World Food Forum in Rome this October through Global Voices, where she’ll present policy solutions on sustainable farming. She’s also been shortlisted for a Nuffield Scholarship—a prestigious program developing future leaders in agriculture.

“Sally Turner is proof that when you equip the right people with the right skills, extraordinary things happen,” said presentation expert and CSP Michelle Bowden. “It’s been an honour to watch her transform her message into a movement.”

Media Contact
Company Name: Michelle Bowden Enterprises
Contact Person: Michelle Bowden
Email: Send Email
Phone: +61 412 391 170
Address:PO Box 1247
City: North Sydney
State: NSW
Country: Australia
Website: https://michellebowden.com.au/

Patti Lynne’s “Pneuma: A True Fable” Weaves Holocaust Memory with Personal Healing in Powerful Debut

A Luminous New Novel Delivers a Timeless Story of Love, Loss, and Connection, Bridging Childhood Trauma and Miracles Found in the Quiet Corners of History and Spirit.

In her powerful debut, Pneuma: A True Fable, author Patti Lynne shares a story that reaches across time, loss, and healing. It’s a deeply personal and unforgettable journey, one that gently moves between the living and the spirit world, the pain we carry, and the hope that finds us.

Told through the lives of two young girls, one from the time of the Holocaust, the other growing up decades later, Pneuma is a moving tribute to the strength of the human spirit and the quiet ways we are all connected. It’s a reminder that some stories stay with us for a reason, and that healing can come when we least expect it even through those we’ve never met.

One Spirit Child. Two Lives Forever Changed

Gerti, a four-year-old spirit child, is born into a Hungarian Jewish family during the darkest days of the Holocaust. She is no ordinary girl. Her mission is divine: to guide the lost souls of 200,000 children who perished in Auschwitz-Birkenau to the peace they were denied in life.

Decades later, Patti, a young American born under the shadow of silence and abuse, carries her own invisible wounds. Marked at birth by a striking port wine stain and later burdened by trauma and illness, Patti’s journey unfolds in parallel to Gerti’s. As her body heals through a life-saving transplant, her spirit awakens to a haunting call that pulls her across oceans and memory to the birch grove in Auschwitz, where Gerti waits.

Where Memory Meets Mystery And History Finds a Voice

Part history, part spirit journey, Pneuma is rooted in real events and shaped by deep emotional truth. It walks gently through some of the darkest chapters in human history where families were torn apart and childhoods ended far too soon and into the quiet struggles hidden inside a home. And yet, within all that sorrow, it finds something extraordinary: the power to heal, sometimes in the most unexpected places.

Patti Lynne’s own story is woven through every page with honesty and heart. Her journey is raw and brave, filled with moments that are hard to face but always guided by a quiet hope that healing is possible, even in the places we thought were beyond repair

Some Stories Don’t Just Touch You, They Stay With You

What makes Pneuma: A True Fable truly special is how deeply it feels. Every word carries the weight of real emotion. Every moment is touched by something quiet and true. Patti Lynne doesn’t just tell a story. She shares something lived and deeply felt, drawn from memory, instinct, and a kind of knowing that speaks straight to the heart.

From the haunting silence of Birkenau to a childhood bedroom in 1960s Turkey, from whispered prayers to a life-changing moment in a distant grove, Pneuma gently leads us through the tender spaces where pain meets grace and where something sacred begins to take root.

What Early Readers Are Saying

“Pneuma: A True Fable is the kind of book that stays with you. It’s gentle, powerful, and full of feeling. Even after you’ve finished reading, it keeps echoing in your heart.” — Trish Kinney, writer and editor

“This story is brave and deeply personal. There is no way to avoid the bitterly honest truth; at the same time, the darkest places can still emit that light.” — Michael Reinhold, literary reviewer

Meet Author Patti Lynne

Patti Lynne has lived a life shaped by resilience, reflection, and a deep curiosity about what lies beyond what we can see. She’s a storyteller who writes from the heart, drawing on her own journey through pain, healing, and unexpected grace. Pneuma is her first book, one born from real experiences and a quiet calling to share them. Patti lives and writes in the American Southwest, where the land itself seems to hold space for the stories she tells.

Availability

Pneuma is available in paperback and eBook formats through Amazon and other major booksellers.

Why This Story Matters Now

Pneuma: A True Fable is more than a book – it is a silent gift. For someone who struggled with being invisible and lonely, and having no clear path ahead, these pages speak to you with quiet sympathy. It’s not claiming to have all the answers but gently reminds us that healing can find the way even in the hardest places.

Open the book. Walk into the grove. Let the story meet you where you are.

Contact Details

Contact with our team for interviews, review copies, or speaking engagements.

Media Contact
Company Name: The Empire Publishers (USA)
Contact Person: Patti Lynne
Email: Send Email
State: Arizona
Country: United States
Website: https://www.theempirepublishers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Patti Lynne’s “Pneuma: A True Fable” Weaves Holocaust Memory with Personal Healing in Powerful Debut

IBN Technologies’ Accounting and Bookkeeping Services Empower New Jersey Businesses to Achieve Financial Clarity

“Accounting and Bookkeeping Services [USA]”
Businesses across New Jersey are increasingly adopting accounting and bookkeeping services to streamline operations, reduce overhead, and maintain compliance. As financial demands rise, companies seek expert-led solutions that deliver cost-effective, secure, and scalable results. IBN Technologies emerges as a trusted provider, offering customized support that improves accuracy and enables strategic financial growth.

Miami, Florida, 17 June 2025 – As financial pressures mount across industries, businesses in New Jersey are turning to accounting and bookkeeping services improve decision-making, boost operational efficiency, and ensure compliance. Small and mid-sized businesses, whether in the retail, construction, professional services, or healthcare sectors, are looking for trustworthy financial solutions that offer insights that can be used beyond simple reporting. The demand points to a significant departure from conventional internal teams in favor of adaptable, expert-driven substitutes that foster long-term expansion.

To choose the optimum structure for their financial management, businesses are also analyzing the difference between bookkeeping and accounting considering increased regulatory scrutiny and internal expenses. Without the expense of full-time personnel, outsourced models provide access to seasoned experts, efficient workflows, and strong financial visibility. In this context, companies such as IBN Technologies are establishing new benchmarks by offering customized, safe, and economical services that are particularly designed to meet the changing demands of the business community in New Jersey.

Simplify Finance and Stay in Control

Start Your Free Trial Today: https://www.ibntech.com/free-trial/

The Rising Complexity of Internal Financial Operations

Basic tracking is frequently the first step in internal financial management, but as firms grow, it soon becomes unsustainable. Growing issues with staffing and compliance confront financial executives and entrepreneurs. Outdated tools and limited capacity can limit performance and raise risk, particularly when important team members go or when company volumes change.

• Delays in monthly closing, affecting timely reports and planning

• Overdependence on specific staff, creating knowledge gaps and bottlenecks

• Difficulty implementing advanced bookkeeping software for small businesses

• Higher costs due to hiring, training, and employee turnover

• Fragmented data sources, reducing accuracy and transparency

To combat these issues, many organizations are exploring outsourced accounting and bookkeeping solutions. IBN Technologies stands out by offering scalable systems designed to eliminate inefficiencies and reduce exposure to risk. This empowers internal teams to focus on revenue-driving initiatives while ensuring their financial records are in expert hands.

Rising Demand for End-to-End Financial Services

A growing number of small company owners in New Jersey are moving toward complete models as they realize the limitations of partial financial support. These comprehensive services provide strategic clarity without putting a burden on internal resources by managing everything from year-end tax support to daily transaction tracking.

✅ Full-cycle accountants bookkeeping services to ensure financial consistency

 

✅ Intelligent reporting that supports accurate forecasting and budgeting

 

✅ Tax preparation aligned with federal and state compliance standards

 

✅ Receivables and payables managed for improved working capital

 

✅ Financial advisory supported by cloud-based tools for smarter decisions

By leveraging systems developed around specific industries, IBN Technologies provides accounting and bookkeeping services that are both efficient and precise. Their flexibility allows for seamless adjustments as businesses grow or pivot, helping maintain compliance and profitability in a constantly changing economic environment.

Outsourcing Drives Real Results

Companies across the state are discovering that partnering with seasoned providers yields not just savings, but better outcomes across the board. IBN Technologies, for example, has built its reputation on measurable client success.

• Serving over 1,500 clients globally, with a 95% client retention rate

• Delivering up to 50% cost savings over in-house options

• Achieving 99% accuracy across all financial reporting metrics

• Secure data handling through encrypted, remote infrastructure

For businesses evaluating company bookkeeping solutions, these performance indicators provide the assurance needed to transition away from traditional methods. The shift is not merely transactional; it is strategic—offering real-time visibility, improved accountability, and peace of mind.

Explore Transparent Pricing Today

See Plan Options: https://www.ibntech.com/pricing/

Transforming Financial Strategy Through Trusted Partnerships

The demand for flexible, responsive, and expert-led financial monitoring keeps growing as businesses deal with ever-increasing complexity. As a result, virtual bookkeeping has emerged as a key enabler—offering real-time access, operational agility, and seamless financial oversight. Today, accounting and bookkeeping services are essential to the implementation of strategic plans rather than being viewed as supporting functions. Companies are switching from internal, static systems to dynamic partnerships that offer cost control, speed, and structure.

IBN Technologies, which combines industry-specific expertise with state-of-the-art tools and individualized assistance, has become a leading solution provider in New Jersey. They are a great option for companies looking for financial stability in unpredictable times because of their emphasis on providing measurable advantages, whether they be cost reductions, compliance assurance, or strategic clarity.

Related Services:           

Outsourced Finance and Accounting: https://www.ibntech.com/finance-and-accounting-services/           

 About IBN Technologies                

IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive efficiency and growth. 

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IBN Technologies’ Accounting and Bookkeeping Services Empower New Jersey Businesses to Achieve Financial Clarity

TEÓNA Releases Empowering New Single “What I Want” – A Bold Anthem for Every Woman Who Once Had a Love So Bad It Felt Good

Rising genre-bending artist TEÓNA has released her bold new single, “What I Want”—an empowering anthem celebrating feminine freedom, self-worth, and unapologetic desire. With a sound that fuses R&B, soul, and pop, the track showcases Teóna’s poetic roots and magnetic vocal presence. Upcoming tour stops include Minneapolis, Havana, New Orleans, Washington D.C., and New York. The single is now streaming on all major platforms.

New York, NY – June 17, 2025 – Rising artist TEÓNA has officially released her latest single, “What I Want”, now available on all major streaming platforms. The track is a sultry, empowering anthem for women who are owning their desires, their space, and their standards—unapologetically.

Blending elements of R&B, soul, and pop with a fresh, confident delivery, “What I Want” captures the essence of feminine power and the freedom that comes with putting yourself first. From the opening beat to the final hook, Teóna’s vocals ride effortlessly over an upbeat, free-spirited production, drawing comparisons to classic sirens like Donna Summer and modern muses like Jhené Aiko.

“Life is for living,” TEÓNA says. “It’s about being honest about what you want—and being unapologetic about it.”

Known for her rich storytelling and magnetic stage presence, TEÓNA fuses her roots in poetry, performance, and disco music to create a unique sound that speaks to women who are choosing themselves in every way—from the boardroom to the bedroom.

With tour dates soon to be announced in Minneapolis, Havana, New Orleans, Washington D.C., and New York, “What I Want” sets the stage for a series of electrifying live performances that promise to leave listeners moved, empowered, and wanting more.

Stream “What I Want” today on Spotify, Apple Music, or your favorite platform, and follow @muse.teona on Instagram for exclusive behind-the-scenes content and upcoming show announcements.

About TEÓNA

TEÓNA is a genre-bending artist, entrepreneur, and storyteller who creates music for the bold, the soft, and the sacred. With roots in the American South and stories that span the globe, her artistry is rooted in freedom, sensuality, and truth.

If you’d like a clean, high-quality file of “What I Want” ready for radio rotation or your DJ set, please don’t hesitate to reach out. TEÓNA is also available for interviews, drops, guest features, and media appearances.

PRESS INQUIRIES & RADIO STREAMING:

Email: music@iamteona.com

Instagram: @muse.teona

Website: iamteona.com

Media Contact
Company Name: Brand Like A Celebrity®?
Contact Person: Tephanie Delaney
Email: Send Email
Country: United States
Website: iamteona.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TEÓNA Releases Empowering New Single “What I Want” – A Bold Anthem for Every Woman Who Once Had a Love So Bad It Felt Good

Buck Stove & Spa Unveils Brand New Website, Bringing Premier Hot Tubs, Stoves, and Fireplaces to Visalia Online

“Buck Stove & Spa Storefront”
The new website serves as a comprehensive showcase for Buck Stove & Spa’s diverse inventory, which includes a wide selection of luxurious hot tubs perfect for relaxation and hydrotherapy, as well as a variety of wood, pellet, and gas stoves engineered for optimal heating efficiency. Visitors can also browse an impressive array of fireplaces, ranging from traditional masonry to contemporary electric models, all designed to add warmth, ambiance, and value to any home.

VISALIA, CA – June 17, 2025 – Buck Stove & Spa, Visalia’s trusted destination for high-quality hot tubs, efficient stoves, and elegant fireplaces, today announced the official launch of its brand new website: www.buckstoveandspas.com. This modern digital platform is designed to enhance the customer experience, making it easier than ever for local residents to explore the company’s extensive product offerings from the comfort of their homes.

The new website serves as a comprehensive showcase for Buck Stove & Spa’s diverse inventory, which includes a wide selection of luxurious hot tubs perfect for relaxation and hydrotherapy, as well as a variety of wood, pellet, and gas stoves engineered for optimal heating efficiency. Visitors can also browse an impressive array of fireplaces, ranging from traditional masonry to contemporary electric models, all designed to add warmth, ambiance, and value to any home.

“We are incredibly excited to launch our new website,” said Bob Haun, Owner of Buck Stove & Spa. “For years, we’ve been dedicated to providing Visalia and the surrounding communities with top-tier products and exceptional service in person. This new online presence allows us to extend that commitment by offering a convenient, accessible way for customers to discover our full range of hot tubs, stoves, and fireplaces before they even step into our showroom. It’s a significant step forward in serving our community better.”

Key features of the new website include:

  • Intuitive Navigation: A user-friendly interface allows for seamless browsing across product categories.
  • Detailed Product Pages: Each product features high-resolution images, comprehensive descriptions, and key specifications.
  • Customer Resources: Information on maintenance, installation, and financing options.
  • Contact & Location Information: Easy access to showroom hours, address, and contact details for personalized assistance.

The launch of the website reflects Buck Stove & Spa’s ongoing commitment to innovation and customer satisfaction, ensuring that the warmth and comfort they provide extends beyond their physical storefront directly to their clients’ fingertips.

About Buck Stove & Spa:

Buck Stove & Spa has proudly served the Visalia community for over 10 years, specializing in the sale, installation, and service of premium hot tubs, wood stoves, pellet stoves, gas stoves, and fireplaces. Committed to quality and customer satisfaction, Buck Stove & Spa helps homeowners create comfortable, efficient, and beautiful living spaces.

Media Contact
Company Name: Buck Stove & Spa
Contact Person: Bob Haun, Owner
Email: Send Email
Phone: (559) 627-2205
Address:1830 W Caldwell Ave
City: Visalia
State: CA
Country: United States
Website: www.buckstoveandspas.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Buck Stove & Spa Unveils Brand New Website, Bringing Premier Hot Tubs, Stoves, and Fireplaces to Visalia Online

Gaby Guha Officially Nominated as Miss Universe Bulgaria 2025

Gaby Guha is representing Bulgaria in Miss Universe 2025, continuing her career in fashion, business, and social advocacy.

Gaby Guha, an international fashion model and entrepreneur, has officially been nominated as Miss Universe Bulgaria 2025. The announcement confirms her participation in the upcoming Miss Universe pageant, representing Bulgaria on a global stage. Known for her modeling work and involvement in philanthropic causes, Guha adds another chapter to her career with this official title.

Originally crowned Miss Europe in 2020, Gaby Guha has steadily built a profile that spans fashion, media, and business. She has worked with several luxury fashion brands, including Chaumet, Elie Saab, Jean Louis David, GAP, Bossini, Triumph Lingerie, and Robert Abi Nader. Her presence has extended to magazine covers such as Prestige, ICON, Gmaro, and L’Officiel. Television appearances on channels including Fashion TV, Canal+, M6, and MTV have helped increase her visibility across Europe and the Middle East.

Her official nomination as Miss Universe Bulgaria follows months of anticipation after she announced her intent to compete in Miss Universe 2025 earlier this year. With this step, Guha now prepares to represent Bulgaria on one of the most recognized global platforms in the world of pageantry.

Beyond her modeling career, Guha is active in business and social initiatives. She is the founder of Gaby Beauty, a cosmetics and skincare brand, and G Global, a real estate investment company. Both ventures reflect her interest in business development and her aim to diversify her professional commitments beyond fashion.

Gaby Guha’s nomination also brings attention to her ongoing work in advocacy. She has supported initiatives focused on education, women’s safety, and health. Her association with The Pink Ribbon Foundation in London highlights her continued interest in causes related to breast cancer awareness and women’s well-being.

Speaking previously about her participation in Miss Universe, Guha emphasized that her involvement is not only about competition but also about representation and influence. She views the platform as a way to highlight issues that matter to her and to support others who are working toward personal and social growth.

With the official confirmation of her title as Miss Universe Bulgaria 2025, Guha is expected to share her preparation journey and upcoming activities with her followers on social media. Her Instagram account, already a source of updates on her modeling and professional life, will continue to offer a closer look into the months ahead as she prepares for the pageant.

Gaby Guha’s selection marks a new development in her career, combining public recognition with an opportunity to represent Bulgaria in front of an international audience. Her focus remains on maintaining a meaningful presence that extends beyond appearances and into areas of work that reflect her values and long-term interests.

For updates, insights, and behind-the-scenes content, Gaby Guha can be followed on Instagram at www.instagram.com/gabyguha

Media Contact
Company Name: Gaby Guha Communication
Contact Person: Media Relations Team
Email: Send Email
Country: United Arab Emirates
Website: www.instagram.com/gabyguha

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gaby Guha Officially Nominated as Miss Universe Bulgaria 2025

Complement 3 Glomerulopathy Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Complement 3 Glomerulopathy Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Complement 3 Glomerulopathy pipeline landscape. It covers the Complement 3 Glomerulopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Complement 3 Glomerulopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Complement 3 Glomerulopathy Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Complement 3 Glomerulopathy Pipeline Outlook Report

Key Takeaways from the Complement 3 Glomerulopathy Pipeline Report

  • In April 2025, Novartis Pharmaceuticals announced a study Baseline/Day 1 visit is equivalent to the End of Treatment visit of the parent study. The study will begin on Day 1 followed by on-site visits every 4 months during the study treatment period. A Safety Follow Up tele-visit must be conducted 7 days after last study treatment to collect information on Adverse Events.
  • DelveInsight’s Complement 3 Glomerulopathy pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Complement 3 Glomerulopathy treatment.
  • The leading Complement 3 Glomerulopathy Companies such as ChemoCentryx, Novartis Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals and others.
  • Promising Complement 3 Glomerulopathy Pipeline Therapies such as Iptcaopan 200 mg, Pegcetacoplan, and others.

Discover how the Complement 3 Glomerulopathy treatment paradigm is evolving. Access DelveInsight’s in-depth Complement 3 Glomerulopathy Pipeline Analysis for a closer look at promising breakthroughs @ Complement 3 Glomerulopathy Clinical Trials and Studies

Complement 3 Glomerulopathy Emerging Drugs Profile

  • Avacopan: Novartis Pharmaceuticals

Avacopan is an orally-administered drug candidate that inhibits the complement C5a receptor, or C5aR, and is being developed for inflammatory and autoimmune diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the natural ligand for C5aR. It is in phase II stage of development to treat C3 Glomerulopathy

  • LNP 023: Novartis Pharmaceuticals

Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, targeting one of the key drivers of these diseases9-11. It has the potential to become the first targeted therapy to delay progression to dialysis in C3G. It is in phase II stage of development to treat C3 Glomerulopathy

The Complement 3 Glomerulopathy Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Complement 3 Glomerulopathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complement 3 Glomerulopathy Treatment.
  • Complement 3 Glomerulopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Complement 3 Glomerulopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Complement 3 Glomerulopathy market

Explore groundbreaking therapies and clinical trials in the Complement 3 Glomerulopathy Pipeline. Access DelveInsight’s detailed report now! @ New Complement 3 Glomerulopathy Drugs

Complement 3 Glomerulopathy Companies

ChemoCentryx, Novartis Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals and others.

Complement 3 Glomerulopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Complement 3 Glomerulopathy Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Complement 3 Glomerulopathy Market Drivers and Barriers, and Future Perspectives

Scope of the Complement 3 Glomerulopathy Pipeline Report

  • Coverage- Global
  • Complement 3 Glomerulopathy Companies- ChemoCentryx, Novartis Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals and others.
  • Complement 3 Glomerulopathy Pipeline Therapies- Iptcaopan 200 mg, Pegcetacoplan, and others.
  • Complement 3 Glomerulopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Complement 3 Glomerulopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Complement 3 Glomerulopathy drug development? Find out in DelveInsight’s exclusive Complement 3 Glomerulopathy Pipeline Report—access it now! @ Complement 3 Glomerulopathy Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Complement 3 Glomerulopathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Drug name: Company name
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Iptacopan: Novartis
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. Drug name: Company name
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Complement 3 Glomerulopathy Key Companies
  20. Complement 3 Glomerulopathy Key Products
  21. Complement 3 Glomerulopathy- Unmet Needs
  22. Complement 3 Glomerulopathy- Market Drivers and Barriers
  23. Complement 3 Glomerulopathy- Future Perspectives and Conclusion
  24. Complement 3 Glomerulopathy Analyst Views
  25. Complement 3 Glomerulopathy Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/complement-3-glomerulopathy-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complement 3 Glomerulopathy Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report

Key Takeaways from the Chronic Lymphocytic Leukemia Pipeline Report

  • In June 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.
  • In June 2025, German CLL Study Group conducted a phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as having at least one of the follow-ing risk factors: 17p-deletion, TP53-mutation or complex karyotype).
  • In June 2025, Acerta Pharma BV organized a Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia.
  • The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
  • Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others.

Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight’s in-depth Chronic Lymphocytic Leukemia Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies

Chronic Lymphocytic Leukemia Emerging Drugs Profile

  • Pirtobrutinib: Loxo Oncology

Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia.

  • Cirmtuzumab: Oncternal Therapeutics

Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL.

  • MS-553: MingSight Pharmaceuticals

MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL.

  • NX-2127: Nurix Therapeutics

NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments.

  • NX-5948: Nurix Therapeutics

NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia.

The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment.
  • Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market

Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight’s detailed report now! @ New Chronic Lymphocytic Leukemia Drugs

Chronic Lymphocytic Leukemia Companies

Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.

Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Lymphocytic Leukemia Pipeline Report

  • Coverage- Global
  • Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
  • Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others.
  • Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight’s exclusive Chronic Lymphocytic Leukemia Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic lymphocytic leukemia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic lymphocytic leukemia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pirtobrutinib: Loxo Oncology
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Cirmtuzumab: Oncternal Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. NX-2127: Nurix Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic lymphocytic leukemia Key Companies
  21. Chronic lymphocytic leukemia Key Products
  22. Chronic lymphocytic leukemia- Unmet Needs
  23. Chronic lymphocytic leukemia- Market Drivers and Barriers
  24. Chronic lymphocytic leukemia- Future Perspectives and Conclusion
  25. Chronic lymphocytic leukemia Analyst Views
  26. Chronic lymphocytic leukemia Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Cutaneous T Cell Lymphoma Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Cutaneous T-cell lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Cutaneous T Cell Lymphoma Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Cutaneous T Cell Lymphoma Pipeline Outlook Report

Key Takeaways from the Cutaneous T Cell Lymphoma Pipeline Report

  • In June 2025, M.D. Anderson Cancer Center announced a study is to determine the overall response rate (ORR), to ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome.
  • In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible light.The study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant’s lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session.
  • DelveInsight’s Cutaneous T Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T Cell Lymphoma treatment.
  • The leading Cutaneous T Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc. and others.
  • Promising Cutaneous T-Cell lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, Quisinostat, APO866, Enzastaurin, bexarotene, Mogamulizumab, Vorinostat, Brentuximab vedotin and others.

Discover how the Cutaneous T Cell Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Cutaneous T Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Cutaneous T Cell Lymphoma Clinical Trials and Studies

Cutaneous T Cell Lymphoma Emerging Drugs Profile

  • HyBryte: Soligenix

HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States.

  • AFM13: Affimed GmbH

AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma.

  • ASTX660: Otsuka Pharmaceutical Co., Ltd

ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL.

  • WUCART007: Wugen

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL.

The Cutaneous T Cell Lymphoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T Cell Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T Cell Lymphoma Treatment.
  • Cutaneous T Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cutaneous T Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T Cell Lymphoma market

Explore groundbreaking therapies and clinical trials in the Cutaneous T Cell Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ New Cutaneous T Cell Lymphoma Drugs

Cutaneous T Cell Lymphoma Companies

HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc. and others.

Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Cutaneous T Cell Lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Cutaneous T Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous T Cell Lymphoma Pipeline Report

  • Coverage- Global
  • Cutaneous T Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc. and others.
  • Cutaneous T-Cell lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, Quisinostat, APO866, Enzastaurin, bexarotene, Mogamulizumab, Vorinostat, Brentuximab vedotin and others.
  • Cutaneous T Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Cutaneous T Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Cutaneous T Cell Lymphoma drug development? Find out in DelveInsight’s exclusive Cutaneous T Cell Lymphoma Pipeline Report—access it now! @ Cutaneous T Cell Lymphoma Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Cutaneous T-cell lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Cutaneous T-cell lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. AFM13: Affimed GmbH
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. WUCART007: Wugen
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Cutaneous T-cell lymphoma Key Companies
  21. Cutaneous T-cell lymphoma Key Products
  22. Cutaneous T-cell lymphoma- Unmet Needs
  23. Cutaneous T-cell lymphoma- Market Drivers and Barriers
  24. Cutaneous T-cell lymphoma- Future Perspectives and Conclusion
  25. Cutaneous T-cell lymphoma Analyst Views
  26. Cutaneous T-cell lymphoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous T Cell Lymphoma Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Complicated Urinary Tract Infections Pipeline Insight 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Complicated Urinary Tract Infections pipeline landscape. It covers the Complicated Urinary Tract Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Complicated Urinary Tract Infection Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Complicated Urinary Tract Infection Pipeline Outlook Report

Key Takeaways from the Complicated Urinary Tract Infection Pipeline Report

  • In June 2025, Menarini Group announced a clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration.
  • In June 2025, Venatorx Pharmaceuticals Inc. conducted a Phase 3 study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis.
  • In June 2025, Rempex organized a study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).
  • DelveInsight’s Complicated Urinary Tract Infection pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Complicated Urinary Tract Infection treatment.
  • The leading Complicated Urinary Tract Infection Companies such as Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and others.
  • Promising Complicated Urinary Tract Infections Pipeline Therapies such as Ceftazidime -avibactam, Cefepime, CXA-101, Ceftazidime, Eravacycline, Ertapenem, Sulopenem and others.

Discover how the Complicated Urinary Tract Infection treatment paradigm is evolving. Access DelveInsight’s in-depth Complicated Urinary Tract Infection Pipeline Analysis for a closer look at promising breakthroughs @ Complicated Urinary Tract Infection Clinical Trials and Studies

Complicated Urinary Tract Infection Emerging Drugs Profile

  • Tebipenem Pivoxil Hydrobromide: Spero Therapeutics

Spero Therapeutics is developing tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) as an oral antibiotic for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) to help patients avoid hospitalizations (stay at home) and/or transition patients home after IV therapy (get home). In September 2020, tebipenem HBr completed a pivotal Phase III trial, ADAPT-PO, for the treatment of cUTI, including acute pyelonephritis (AP). ADAPT-PO is a landmark trial that is the first ever to test an all oral regimen against an all intravenous (IV) regimen for the treatment of cUTI. The global, randomized, placebo-controlled ADAPT-PO trial evaluated the safety and efficacy of tebipenem HBr in hospitalized adult patients with cUTI or AP. Data from the trial demonstrated that oral tebipenem HBr was statistically non-inferior to IV ertapenem in the treatment of patients with cUTI and patients with AP. If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and AP.Following feedback from the US FDA at Spero’s recent Type A meeting, Spero will conduct an additional phase III trial to support the regulatory submission.

  • Sulopenem: Iterum Therapeutics

Sulopenem is an orally bioavailable, broad-spectrum penem β-lactam antibiotic which is being developed for the treatment of infections caused by multi-drug resistant bacteria. Sulopenem was discovered in the laboratories of Pfizer Inc. in the 1980s and was first developed with an intravenous (IV) formulation only. The company completed an extensive pre-clinical program, followed by human studies. Later, an oral formulation was developed and tested in Phase I and Phase II trials. In May 2022, Iterum Therapeutics plc announced it met with the US Food and Drug Administration (“FDA”) on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company’s new drug application (“NDA”) for oral sulopenem etzadroxil-probenecid (“oral sulopenem”) for the treatment of uncomplicated urinary tract infections (“uUTI”). Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment uncomplicated urinary tract infections.

The Complicated Urinary Tract Infection Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Complicated Urinary Tract Infection with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complicated Urinary Tract Infection Treatment.
  • Complicated Urinary Tract Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Complicated Urinary Tract Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Complicated Urinary Tract Infection market

Explore groundbreaking therapies and clinical trials in the Complicated Urinary Tract Infection Pipeline. Access DelveInsight’s detailed report now! @ New Complicated Urinary Tract Infection Drugs

Complicated Urinary Tract Infection Companies

Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and others

Complicated Urinary Tract Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Complicated Urinary Tract Infection Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Complicated Urinary Tract Infection Market Drivers and Barriers, and Future Perspectives

Scope of the Complicated Urinary Tract Infection Pipeline Report

  • Coverage- Global
  • Complicated Urinary Tract Infection Companies- Spero Therapeutics, Iterum Therapeutics, Venatorx Pharmaceuticals Inc., Nabriva Therapeutics, Allecra Therapeutics, Wockhardt, MerLion Pharmaceuticals, and others.
  • Complicated Urinary Tract Infections Pipeline Therapies- Ceftazidime -avibactam, Cefepime, CXA-101, Ceftazidime, Eravacycline, Ertapenem, Sulopenem and others.
  • Complicated Urinary Tract Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Complicated Urinary Tract Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Complicated Urinary Tract Infection drug development? Find out in DelveInsight’s exclusive Complicated Urinary Tract Infection Pipeline Report—access it now! @ Complicated Urinary Tract Infection Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Complicated Urinary Tract Infections: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Tebipenem Pivoxil Hydrobromide: Spero Therapeutics
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. ETX0282CPDP: Entasis Therapeutics
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Complicated Urinary Tract Infections Key Companies
  17. Complicated Urinary Tract Infections Key Products
  18. Complicated Urinary Tract Infections- Unmet Needs
  19. Complicated Urinary Tract Infections- Market Drivers and Barriers
  20. Complicated Urinary Tract Infections- Future Perspectives and Conclusion
  21. Complicated Urinary Tract Infections Analyst Views
  22. Complicated Urinary Tract Infections Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight